M0249 Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose
Short descriptor: Adm tocilizu covid-19 1st
Look up M0249 alongside ICD-10-CM diagnoses, the HCPCS Table of Drugs, and the AI coding assistant.
M0249 is the HCPCS Level II code for Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose (2026). It belongs to Section M — Medical Services. Under Medicare, its coverage status is: Carrier judgment. Part B pricing methodology: Vaccinations.
Classification & CMS Attributes
- Section
- M: Medical Services
- Medicare Coverage
- Carrier judgment (code C)
- Part B Pricing
- Vaccinations (indicator 54)
- Type of Service
- Pneumococcal/flu/hepatitis B vaccine
- Effective Date
- 2021-06-24
- 2026 Maintenance
- No change this year
References
Cite This Page
Reference M0249 with the canonical source and edition:
M0249 — Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, first dose. ICD-10 Coding Pro (HCPCS Level II 2026). https://icd10codingpro.com/hcpcs-codes/M0249
Canonical URL: https://icd10codingpro.com/hcpcs-codes/M0249